Ali Khamesipour Selected Research

Leishmaniasis

8/2022	An alphavirus-derived self-amplifying mRNA encoding PpSP15-LmSTI1 fusion protein for the design of a vaccine against leishmaniasis.
11/2021	Old world cutaneous leishmaniasis in Iran: clinical variants and treatments.
10/2021	Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica: study protocol for a randomized, controlled trial.
6/2021	Potential biomarkers of immune protection in human leishmaniasis.
1/2021	Evolution of antigen-specific immune responses in cutaneous leishmaniasis patients.
1/2020	Human immune response to Phlebotomus sergenti salivary gland antigens in a leishmaniasis-endemic focus in Iran.
1/2020	Development of nano-carriers for Leishmania vaccine delivery.
1/2019	Evaluation of Immune Response against Leishmaniasis in BALB/c Mice Immunized with Cationic DOTAP/DOPE/CHOL Liposomes Containing Soluble Leishmania major Antigens.
1/2019	Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
6/2018	Cationic liposomes formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ali Khamesipour Research Topics

Disease

48	Leishmaniasis 08/2022 - 12/2002
40	Cutaneous Leishmaniasis 06/2022 - 01/2005
18	Infections 08/2022 - 08/2007
4	Visceral Leishmaniasis (Kala Azar) 07/2021 - 09/2004
3	Hypersensitivity (Allergy) 07/2021 - 10/2018
2	Pain (Aches) 01/2022 - 11/2013
2	Drug-Related Side Effects and Adverse Reactions 01/2022 - 07/2018
2	Erythema 01/2022 - 09/2018
2	Pruritus (Itching) 01/2017 - 12/2006
2	Malaria 01/2015 - 12/2014
2	Communicable Diseases (Infectious Diseases) 11/2014 - 12/2013
2	Dehydration (Water Stress) 04/2009 - 08/2007
1	Eosinophilia 01/2022
1	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2022
1	Acute Generalized Exanthematous Pustulosis 01/2022
1	Erysipeloid 11/2021
1	Lymphadenitis (Adenitis) 11/2021
1	Disease Progression 06/2021
1	Bites and Stings (Sting) 01/2020
1	Cicatrix (Scar) 01/2018
1	Warts (Wart) 01/2018

Drug/Important Bio-Agent (IBA)

29	VaccinesIBA 08/2022 - 12/2002
19	AntigensIBA 08/2022 - 08/2007
15	Liposomes (Liposome)IBA 08/2019 - 08/2007
14	Meglumine AntimoniateIBA 01/2022 - 01/2005
9	CytokinesIBA 07/2021 - 10/2010
8	Amphotericin B (Amphotericin)FDA LinkGeneric 12/2021 - 12/2015
7	Pharmaceutical PreparationsIBA 01/2022 - 05/2006
6	Biomarkers (Surrogate Marker)IBA 06/2021 - 11/2006
4	Proteins (Proteins, Gene)FDA Link 08/2022 - 10/2010
4	Leishmaniasis VaccinesIBA 11/2014 - 06/2008
4	OligodeoxyribonucleotidesIBA 11/2012 - 04/2008
4	CPG-oligonucleotideIBA 10/2011 - 08/2007
3	Interleukin-10 (Interleukin 10)IBA 06/2021 - 10/2019
3	Mustard Gas (Sulfur Mustard)IBA 01/2017 - 11/2013
3	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 10/2012 - 03/2005
2	Interleukin-12 (IL 12)IBA 06/2021 - 06/2008
2	EnzymesIBA 01/2020 - 01/2017
2	ImmunosorbentsIBA 01/2020 - 01/2017
2	Phosphates (Orthophosphate)IBA 01/2020 - 07/2012
2	1,2- dioleoyloxy- 3- (trimethylammonium)propaneIBA 01/2019 - 12/2013
2	Immunoglobulin G (IgG)IBA 02/2018 - 11/2013
2	Membrane Glycoproteins (Membrane Glycoprotein)IBA 02/2018 - 12/2012
2	Therapeutic UsesIBA 01/2018 - 11/2014
2	Imiquimod (Aldara)FDA LinkGeneric 01/2018 - 12/2006
2	LigandsIBA 01/2018 - 01/2015
2	SolutionsIBA 10/2016 - 01/2005
2	AlginatesIBA 01/2016 - 10/2011
2	Interleukin-6 (Interleukin 6)IBA 06/2014 - 09/2012
2	aluminum sulfate (alum)IBA 11/2006 - 09/2004
1	Messenger RNA (mRNA)IBA 08/2022
1	Recombinant ProteinsIBA 08/2022
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 06/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	Lamotrigine (Lamictal)FDA LinkGeneric 01/2022
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2022
1	Carbamazepine (Tegretol)FDA LinkGeneric 01/2022
1	HLA-A31 antigenIBA 01/2022
1	HLA-B Antigens (HLA-B)IBA 01/2022
1	Glycyrrhizic Acid (Glycyrrhizin)IBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022
1	Melanins (Melanin)IBA 01/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022
1	HLA-DRB1 Chains (HLA DRB1)IBA 01/2022
1	gingerolIBA 12/2021
1	liposomal amphotericin B FDA Link 10/2021
1	Immunologic Factors (Immunomodulators)IBA 06/2021
1	Olive OilIBA 01/2021
1	ChitosanIBA 01/2021
1	bicinchoninic acidIBA 01/2020
1	AntibodiesIBA 01/2020
1	Polysorbates (PSML)FDA Link 01/2020
1	Salivary Proteins and PeptidesIBA 01/2020
1	polyvinylidene fluoride (PVDF)IBA 01/2020
1	polyacrylamideIBA 01/2020
1	Horseradish PeroxidaseIBA 01/2020
1	Bovine Serum AlbuminIBA 01/2020
1	Sodium Dodecyl Sulfate (Sodium Lauryl Sulfate)IBA 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 12/2019
1	leishmaninIBA 12/2019
1	theasinensin AIBA 12/2019
1	DNA VaccinesIBA 12/2019
1	chloriteIBA 11/2019
1	SodiumIBA 11/2019
1	Interleukin-5 (Interleukin 5)IBA 10/2019
1	miltefosine (Impavido)IBA 08/2019
1	Attenuated VaccinesIBA 01/2019
1	Betulinic AcidIBA 01/2018
1	monophosphoryl lipid AIBA 01/2018
1	Antiparasitic Agents (Antiparasitics)IBA 01/2018

Therapy/Procedure

5	Therapeutics 01/2017 - 10/2012
2	Injections 01/2022 - 12/2002
2	Microspheres (Microsphere) 01/2016 - 10/2011
2	Drug Therapy (Chemotherapy) 01/2015 - 11/2014
2	Immunotherapy 11/2014 - 06/2012
2	Fluid Therapy (Oral Rehydration Therapy) 04/2009 - 08/2007
1	Transplantation 11/2021
1	Salvage Therapy 11/2019
1	Induced Hyperthermia (Thermotherapy) 01/2018
1	Cryotherapy (Therapy, Cold) 01/2018